In the Original Investigation titled “Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis,”1 published in the March 2022 issue of JAMA Dermatology, it was incorrectly stated that Dr Wehner received personal fees as a Cancer Prevention and Research Institute of Texas Scholar in Cancer Research. The disclosure statement should have read: “Dr Wehner is a Cancer Prevention and Research Institute of Texas Scholar in Cancer Research.” This article has been corrected online.

1.Bommareddy  K, Hamade  H, Lopez-Olivo  MA, Wehner  M, Tosh  T, Barbieri  JS.  Association of spironolactone use with risk of cancer: a systematic review and meta-analysis.   JAMA Dermatol. 2022;158(3):275-282. doi:10.1001/jamadermatol.2021.5866PubMedGoogle ScholarCrossref